Bioelectronic medicine refers to a relatively new field of therapeutics that uses miniaturized, implantable devices to regulate neuronal activity. These devices can potentially treat not only disorders of the nervous system, but also inflammatory processes and muscle activity, making them relevant as potential ALS therapeutics. GlaxoSmithKline (GSK) has demonstrated its growing interest in the field by invested $50 million in a new venture capital arm to fund bioelectronics technologies, called Action Potential Venture Capital. In addition, they launched a $1 million Bioelectronics Innovation Challenge last December. They have now announced a $5 million fund to back academic scientists and companies seeking to solve this challenge. All technologies developed with these funds will be made freely available to the research community.
Read more about this exciting, futuristic technology here.Share this: